ASLAN Pharmaceuticals
21
0
0
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
9.5%
2 terminated/withdrawn out of 21 trials
88.9%
+2.4% vs industry average
0%
0 trials in Phase 3/4
13%
2 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis
Role: lead
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Role: lead
Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants
Role: lead
Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)
Role: lead
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
Role: lead
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
Role: lead
A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia
Role: lead
ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin
Role: collaborator
Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC
Role: lead
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
Role: lead
Study of ASLAN004 in Healthy Subjects
Role: lead
Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine
Role: lead
Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib
Role: lead
A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
Role: lead
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy
Role: lead
Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
Role: lead
Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
Role: lead
A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours
Role: lead
A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects
Role: lead
Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003
Role: lead